Roth Capital Initiates Coverage on Akero Therapeutics (NASDAQ:AKRO)

Research analysts at Roth Capital started coverage on shares of Akero Therapeutics (NASDAQ:AKRO) in a note issued to investors on Monday, reports. The brokerage set a “buy” rating and a $34.00 price target on the stock. Roth Capital’s target price points to a potential upside of 65.61% from the company’s previous close.

Separately, JPMorgan Chase & Co. reiterated a “sell” rating and set a $18.00 price target on shares of ABB in a report on Monday.

Shares of Akero Therapeutics stock opened at $20.53 on Monday. Akero Therapeutics has a 1-year low of $16.06 and a 1-year high of $21.94.

In other news, Director Seth Loring Harrison bought 900,000 shares of Akero Therapeutics stock in a transaction dated Monday, June 24th. The stock was bought at an average cost of $16.00 per share, for a total transaction of $14,400,000.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Global Strategic Fund I. Venbio bought 250,000 shares of Akero Therapeutics stock in a transaction dated Monday, June 24th. The stock was purchased at an average price of $16.00 per share, with a total value of $4,000,000.00. The disclosure for this purchase can be found here.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development and commercialization of transformative treatments for serious metabolic diseases with high unmet medical need. Its lead product candidate is AKR-001, which completed Phase Ib clinical trial for the treatment of non-alcoholic steatohepatitis disease.

Featured Article: NASDAQ Stock Market Explained

Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with's FREE daily email newsletter.